{"id":19162,"date":"2025-03-21T13:29:26","date_gmt":"2025-03-21T06:29:26","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=19162"},"modified":"2025-03-21T13:29:26","modified_gmt":"2025-03-21T06:29:26","slug":"akesos-cadonilimab-combined-with-concurrent-chemoradiotherapy-demonstrates-promising-efficacy-in-locally-advanced-cervical-cancer-data-published-at-the-2025-sgo-annual-meeting","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=19162","title":{"rendered":"Akeso&#8217;s Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting"},"content":{"rendered":"<p><span class=\"legendSpanClass\"><span class=\"xn-location\">HONG KONG<\/span>, March 21, 2025 \/PRNewswire\/ &#8212; Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18\/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1\/CTLA-4 bispecific antibody, cadonilimab (AK104), in combination with concurrent chemoradiotherapy (CCRT) for the treatment of locally advanced cervical cancer.<\/span><\/p>\n<p>Currently, CCRT is the standard of care for locally advanced cervical cancer, but approximately 30%-40% of patients experience relapse or disease progression within five years. Cadonilimab, with its unique dual-target mechanism, is designed to simultaneously inhibit the PD-1 and CTLA-4 immune checkpoint pathways. It has received approval from the National Medical Products Administration (NMPA) in <span class=\"xn-location\">China<\/span> for use in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy. The Phase III COMPASSION-16 study further confirmed that cadonilimab, when combined with platinum-based chemotherapy (with or without bevacizumab), significantly improves progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. Based on these compelling results, the supplemental New Drug Application (sNDA) for cadonilimab as a first-line treatment for persistent, recurrent, or metastatic cervical cancer is currently under regulatory review.<\/p>\n<p>At this year&#8217;s SGO, data from the COMPASSION-18 study highlighted the exceptional efficacy seen in patients receiving cadonilimab in combination with CCRT during the safety run-in phase. The results demonstrate the considerable therapeutic potential of cadonilimab combined with CCRT for locally advanced cervical cancer. <b>The study included a more challenging patient cohort, with a notably higher proportion of patients having PD-L1 CPS &lt;1 (38.2%) and an ECOG performance status of 1 (52.9%) compared to other similar studies.<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Overall Response Rate (ORR)<\/b>: The evaluable patients achieved a remarkable <b>ORR of 100%<\/b>, with a<b> complete response (CR) rate of 84.8%<\/b> and a <b>partial response (PR) rate of 15.2%<\/b>, which significantly outperformed data from other comparable studies. The median duration of response (DoR) has yet to be reached.<\/li>\n<li><b>Progression-Free Survival (PFS)<\/b>: While the median PFS has not been reached, the <b>12-month PFS rate was 74.9%.<\/b><\/li>\n<li><b>Subgroup Analysis:<\/b> Patients with PD-L1 CPS \u22651, ECOG 0, and those not infected with COVID-19 derived even greater benefit from the treatment, with 12-month PFS rates of 85%, 87.5%, and 81.3%, respectively.<\/li>\n<li><b>Safety Profile<\/b>: Cadonilimab combined with CCRT exhibited a favorable safety profile, demonstrating good tolerability and manageable adverse events. Notably, there were no treatment-related deaths (TRAE) and no new safety concerns were identified.<\/li>\n<\/ul>\n<p>Cadonilimab is making significant progress in treating both recurrent\/metastatic and locally advanced cervical cancer, establishing a comprehensive therapeutic approach. The positive results from the COMPASSION-18 study reinforce its potential in a broader patient population. As clinical development continues, cadonilimab is set to redefine cervical cancer treatment, offering long-term survival benefits to more patients.<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">HONG KONG<\/span>, March 21, 2025 \/PRNewswire\/ &#8212; Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18\/AK104-305 study, at the 2025 Annual Meeting of the Society of Gynecologic Oncology (SGO). The study evaluates the global first-in-class PD-1\/CTLA-4 bispecific antibody, cadonilimab (AK104), in combination with concurrent chemoradiotherapy (CCRT) for the treatment of locally advanced cervical cancer.<\/span><\/p>\n<p>Currently, CCRT is the standard of care for locally advanced cervical cancer, but approximately 30%-40% of patients experience relapse or disease progression within five years. Cadonilimab, with its unique dual-target mechanism, is designed to simultaneously inhibit the PD-1 and CTLA-4 immune checkpoint pathways. It has received approval from the National Medical Products Administration (NMPA) in <span class=\"xn-location\">China<\/span> for use in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy. The Phase III COMPASSION-16 study further confirmed that cadonilimab, when combined with platinum-based chemotherapy (with or without bevacizumab), significantly improves progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. Based on these compelling results, the supplemental New Drug Application (sNDA) for cadonilimab as a first-line treatment for persistent, recurrent, or metastatic cervical cancer is currently under regulatory review.<\/p>\n<p>At this year&#8217;s SGO, data from the COMPASSION-18 study highlighted the exceptional efficacy seen in patients receiving cadonilimab in combination with CCRT during the safety run-in phase. The results demonstrate the considerable therapeutic potential of cadonilimab combined with CCRT for locally advanced cervical cancer. <b>The study included a more challenging patient cohort, with a notably higher proportion of patients having PD-L1 CPS &lt;1 (38.2%) and an ECOG performance status of 1 (52.9%) compared to other similar studies.<\/b><\/p>\n<ul type=\"disc\">\n<li><b>Overall Response Rate (ORR)<\/b>: The evaluable patients achieved a remarkable <b>ORR of 100%<\/b>, with a<b> complete response (CR) rate of 84.8%<\/b> and a <b>partial response (PR) rate of 15.2%<\/b>, which significantly outperformed data from other comparable studies. The median duration of response (DoR) has yet to be reached.<\/li>\n<li><b>Progression-Free Survival (PFS)<\/b>: While the median PFS has not been reached, the <b>12-month PFS rate was 74.9%.<\/b><\/li>\n<li><b>Subgroup Analysis:<\/b> Patients with PD-L1 CPS \u22651, ECOG 0, and those not infected with COVID-19 derived even greater benefit from the treatment, with 12-month PFS rates of 85%, 87.5%, and 81.3%, respectively.<\/li>\n<li><b>Safety Profile<\/b>: Cadonilimab combined with CCRT exhibited a favorable safety profile, demonstrating good tolerability and manageable adverse events. Notably, there were no treatment-related deaths (TRAE) and no new safety concerns were identified.<\/li>\n<\/ul>\n<p>Cadonilimab is making significant progress in treating both recurrent\/metastatic and locally advanced cervical cancer, establishing a comprehensive therapeutic approach. The positive results from the COMPASSION-18 study reinforce its potential in a broader patient population. As clinical development continues, cadonilimab is set to redefine cervical cancer treatment, offering long-term survival benefits to more patients.<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-19162","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/19162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19162"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/19162\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}